(Q36747223)

16 August 2017

1 reference

title

Drug insight: VEGF as a therapeutic target for breast cancer (English)

1 reference

16 August 2017

1 reference

1

Bryan P Schneider

1 reference

16 August 2017

George W Sledge

2

1 reference

16 August 2017

publication date

1 March 2007

1 reference

Nature Clinical Practice Oncology

16 August 2017

published in

1 reference

16 August 2017

volume

4

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

181-189

1 reference

Transplacental carcinogenesis by stilbestrol

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Role of vascular endothelial growth factor in regulation of physiological angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Angiogenesis: A Marker for Neoplastic Transformation of Mammary Papillary Hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

The biology of vascular endothelial growth factors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Angiogenesis as a therapeutic target

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Redefining the target: chemotherapeutics as antiangiogenics

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

What is targeted therapy?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

A cancer therapy resistant to resistance

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Angiogenesis of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0740

7 January 2021

Identifiers

DOI

10.1038/NCPONC0740

1 reference

16 August 2017

1 reference